Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01303432
Other study ID # CTNS 001_03_2010
Secondary ID
Status Completed
Phase N/A
First received February 21, 2011
Last updated September 13, 2012
Start date September 2010
Est. completion date June 2011

Study information

Verified date September 2012
Source Bioiberica
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the daily eating of a yogurt supplemented with Mobile is effective in improving joint function and quality of life of individuals with low intensity gonalgia.


Description:

The prevalence of low intensity gonalgia is relatively high in western population. The purpose of the present intervention study is to determine whether the daily consumption of a yogurt supplemented with Mobile is effective in improving joint function and quality of life of individuals with low intensity gonalgia. Previous research using in vitro and animal models have demonstrated the efficacy of Mobilee in reducing inflammation and promoting anabolic responses in joint tissues. In addition, in two previous human intervention trials, the effects of Mobilee in joint function had been assessed using isokinetic tests. The present trial aims to confirm those previous results.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date June 2011
Est. primary completion date March 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- Adult (between 20 and 70 years of age)

- Subject with low intensity knee gonalgia (VAS pain intensity between 3 and 5cm during at least the last 6 months)

- Healthy individual according to its medical records, physical and laboratorial parameters

- Positive informed consent

Exclusion Criteria:

- Individuals requiring acetaminophen or any other drug to control pain

- Active rheumatoid arthritis or any other inflammatory joint disease

- Oral treatment with corticosteroids 4 weeks before selection

- Intra-articular treatment with corticosteroids 3 months before selection

- Significant injury of the study joint 12 months before selection

- Individuals receiving any drug or supplement for osteoarthritis

- Individuals requiring any type of medical prescription to control pain

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Yogurt supplemented with Mobilee
One yogurt (125mL) per day including 80mg of Mobilee
Yogurt
One yogurt (125mL) per day

Locations

Country Name City State
Spain Hospital Universitari Sant Joan de Reus Reus Tarragona

Sponsors (2)

Lead Sponsor Collaborator
Bioiberica Technological Centre of Nutrition and Health

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in isokineic assessment of muscular strength The muscular isokinetic assessment determines peak torque, power mean and total work of a certain joint using a dynamometric computerized system. The principal parameter is the change from baseline in the peak torque of the affected joint in extension at a speed of 240º/sec measured in Nm (Newton-meter). 3 months No
Secondary Change from baseline in isokinetic assessment of muscular strength (other conditions) Change from baseline of peak torque (Nm), power mean (W) and total work (J) of the affected joint in extension at 180º/sec, and in flexion at 240º/sec and 180º/sec. 3 months No
Secondary Assessment of joint swelling, effusion Ultrasonography: Study of the synovial effusion degree (if any) measured in the longitudinal axis of the suprapatellar recess of the affected knee.Results are expressed as change from baseline in mm. 3 months No
Secondary Pain assessment (VAS) Time evolution of pain intensity as measured by Visual Analogue Scale (mm). 3 months No
Secondary SF-36 Health questionnaire Questionnaire SF36-v2 to measure physical and mental health. 3 months No
Secondary Number of Participants with Adverse Events The safety assessment includes a register of the appearance of adverse events along the 3 months of the study 3 months Yes
Secondary Subjective evaluation of the intervention Questionnaire to evaluate the subjective perception of the efficacy of the intervention. 3 months No
Secondary Change from baseline in systolic blood pressure, hearth rate, general biochemical profile and body mass index at 3 months Safety assessment includes an evaluation at 3 months of changes from baseline on systolic blood pressure, hearth rate, general biochemical profile and body mass index 3 months Yes

External Links